Liquidia Corporation (LQDA)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$27.64−3.49%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $2.5B
- P/E (trailing)
- 19.9
- Forward P/E
- 11.5
- 52-week range
- $21.94 – $93.61
- 52-week change
- +15.02%
- EPS (trailing)
- $1.39
- Analyst rating
- 2.3 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $158M (+1031.18%)
- Net income
- −$68.9M
- Operating margin
- −32.5%
- Diluted EPS
- −$0.80
- Free cash flow
- −$40.0M
From the company’s annual report on SEC EDGAR.
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles.
Headquarters: Morrisville, United States · 216 employees · liquidia.com